Ensysce Biosciences Inc (ENSC)

0.22 -0.01 (-2.61%)
Closed USD Disclaimer
0.22 0.00 (0.00%)

Ensysce Biosciences Inc Company Profile

Equity Type
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Contact Information
La Jolla,92037 United States
858 263 4196
Top Executives
D. Lynn Kirkpatrick 64 2009 President, CEO & Director
Steven R. Martin 60 0000 Independent Director
Robert G. Gower 83 2008 Independent Chairman of the Board
Lee M. Rauch 67 2022 Independent Director
Richard C. Dart 0 0000 Member of the Clinical Advisory Board
Jeffrey A. Gudin 57 0000 Member of the Clinical Advisory Board
Andrew K. Benton 69 2019 Independent Director
Hui-Chung Chang 66 2016 Independent Director
Lynn R. Webster 0 0000 Member of the Clinical Advisory Board
Curtis Rosebraugh 64 2021 Independent Director
Adam S. Levin 43 2021 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.